How are new fludarabine conditioning combinations impacting transplant outcomes?

During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?


Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML and MDS.


Hosted on Acast. See acast.com/privacy for more information.

More from AML Hub

  1. 03:36What were your highlights from ASH 2023?Apr 29, 2024
  2. 09:19What are the challenges associated with CAR T-cell therapy in patients with AML?Apr 25, 2024
  3. 07:27How might the MORPHO trial of gilteritinib impact clinical practice?Apr 08, 2024
  4. 11:49Risk stratification and guidelines in AML managementJan 08, 2024
  5. 06:04How are new fludarabine conditioning combinations impacting transplant outcomes?Apr 22, 2022
  6. 06:08Should pre-transplant MRD be used to guide treatment in AML?Jul 10, 2021
  7. 13:54Should pre-transplant MRD be used to guide treatment in AML?Jun 25, 2021
  8. 05:03Should pre-transplant MRD be used to guide treatment in AML?Jun 23, 2021
  9. 05:22Can HMA maintenance therapy improve eligibility for HSCT?Mar 17, 2021
  10. 16:07ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?Feb 02, 2021